Guines Llc Purchases 7,321 Shares of biote Corp. (NASDAQ:BTMD) Stock

biote Corp. (NASDAQ:BTMD - Get Free Report) major shareholder Guines Llc bought 7,321 shares of the stock in a transaction on Thursday, April 3rd. The shares were acquired at an average cost of $3.24 per share, for a total transaction of $23,720.04. Following the completion of the transaction, the insider now directly owns 4,040,868 shares of the company's stock, valued at approximately $13,092,412.32. The trade was a 0.18 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Guines Llc also recently made the following trade(s):

• On Wednesday, April 9th, Guines Llc bought 13,532 shares of biote stock. The stock was purchased at an average price of $3.21 per share, for a total transaction of $43,437.72.
• On Monday, April 7th, Guines Llc purchased 43,378 shares of biote stock. The shares were acquired at an average price of $3.15 per share, with a total value of $136,640.70.
• On Monday, March 31st, Guines Llc bought 106,000 shares of biote stock. The shares were purchased at an average cost of $3.32 per share, for a total transaction of $351,920.00.
• On Monday, March 17th, Guines Llc acquired 100 shares of biote stock. The shares were acquired at an average cost of $3.74 per share, with a total value of $374.00.
• On Thursday, March 13th, Guines Llc purchased 750,000 shares of biote stock. The stock was bought at an average cost of $3.22 per share, for a total transaction of $2,415,000.00.

biote Stock Up 9.0 %

NASDAQ:BTMD traded up $0.30 during trading hours on Friday, hitting $3.65. 224,626 shares of the stock were exchanged, compared to its average volume of 185,298. The company has a market capitalization of $199.69 million, a P/E ratio of 14.04 and a beta of 1.17. biote Corp. has a twelve month low of $3.04 and a twelve month high of $8.44. The company's 50 day moving average is $4.06 and its two-hundred day moving average is $5.19.

Remove Ads

Institutional Trading of biote

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its holdings in biote by 0.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company's stock worth $4,211,000 after purchasing an additional 3,065 shares during the period. State Street Corp increased its position in shares of biote by 13.7% in the third quarter. State Street Corp now owns 475,491 shares of the company's stock valued at $2,653,000 after acquiring an additional 57,290 shares during the last quarter. Kanen Wealth Management LLC bought a new position in shares of biote in the fourth quarter valued at $1,791,000. Northern Trust Corp increased its stake in shares of biote by 9.9% during the 4th quarter. Northern Trust Corp now owns 288,336 shares of the company's stock worth $1,782,000 after purchasing an additional 25,873 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in biote by 24.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 272,377 shares of the company's stock valued at $1,520,000 after buying an additional 54,302 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Craig Hallum cut their target price on shares of biote from $12.00 to $8.00 and set a "buy" rating for the company in a research note on Thursday, March 13th.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.